page

Developing clinical guidelines for the diagnosis, management, and support of myeloma patients

This project was conducted between 2009-2012.

Aim of project

The main purpose of this project was to maintain and develop a set of clinical guidelines for the diagnosis and management of myeloma and related conditions (e.g. MGUS, AL amyloidosis, plasmacytoma) that provides guidance to clinicians involved in the supportive care of patients with myeloma.

Project summary

Guidelines for the diagnosis and management of myeloma had previously been published in 2006. This project updated the guidance with two areas of focus: “Diagnosis and management of multiple myeloma”, and “Supportive care in multiple myeloma”. To produce these guidelines the project team established working groups and reviewed the relevant literature that was available until mid-2010. The project used evidence from published randomized control trials to develop key recommendations or, if there was no data available, the recommendations were formed on the basis of a review of the literature and consensus expert opinion.

The “Diagnosis and management of multiple myeloma” guidelines summarized the current consensus for diagnosis and management with a focus on: diagnosis, prognostic factors and disease monitoring; imaging techniques; management of common medical emergencies; bone disease; renal impairment; induction therapy; refractory disease; high dose therapy and autologous stem cell transplantation; allogeneic stem cell transplantation; maintenance therapy; relapsed myeloma; and patient information and support

The “Supportive care in multiple myeloma” guidelines summarized the current consensus for supportive care in myeloma with a focus on: pain management; peripheral neuropathy; anaemia; haemostasis and thrombosis issues; other symptom control including gastrointestinal, sedation/fatigue, and mucositis; bisphosphonate-induced osteonecrosis of the jaw; complementary therapies; and end of life care.

Who was involved with the project

This project included involvement of patient advocacy through Myeloma UK, review by the UK Myeloma Forum (UKMF), the Executive and British Committee for Standards in Haematology (BCSH) Committees and a British Society for Haematology (BSH) sounding board.

How this project will help Myeloma patients

This project provides updated consensus recommendations for clinicians to improve the care of myeloma patients.

Acknowledgements and funding

This work was funded by a Myeloma UK Educational grant.

Outputs

The guidelines were made available on the British Society for Haematology website and were published in two articles in the British Journal of Haematology in May 2011 which you can read here and here.